盐酸沙拉沙星可溶性粉在竹丝鸡体内的残留研究

Residue Depletion of Sarafloxacin Soluble Powder in Bamboo Chickens

摘要: 为评价盐酸沙拉沙星可溶性粉在竹丝鸡体内的残留消除规律，本研究分别采用混饮(50 mg/L)与灌胃(10 mg/kg)两种方式对竹丝鸡进行给药，并监测不同组织(肌肉、皮脂、肝脏、肾脏)在停药后不同时间点的药物残留情况。结果表明，沙拉沙星在竹丝鸡体内的消除具有明显的组织差异性。在停药后7天，肌肉与皮脂组织的残留浓度仍显著高于最高残留限量(MRL)，存在食品安全风险；而肝脏与肾脏残留浓度随时间延长下降较快。研究结果提示，针对竹丝鸡使用盐酸沙拉沙星，应延长临床休药期，建议休药期不少于35~49天，但这需要更大规模的田间试验证实，以确保肉制品安全。本研究首次系统构建了竹丝鸡这一地方特色品种的沙拉沙星残留消除动力学模型，填补了我国地方鸡种在喹诺酮类药物使用规范中的数据空白。研究不仅验证了药物在组织中的分布规律，更通过长期动态监测，量化了“安全阈值”与“个体变异”的关系，为制定差异化休药期提供了科学依据，对推动“精准用药”与“减抗行动”具有实践价值。

Abstract: To evaluate the residue elimination pattern of sarafloxacin soluble powder in Silkie chickens, this study administered the drug to Silkie chickens using two different methods: mixed drinking (50 mg/L) and oral gavage (10 mg/kg). The drug residues in different tissues (muscle, skin fat, liver, and kidney) were monitored at various time points after drug withdrawal. The results indicated that the elimination of sarafloxacin in Silkie chickens exhibited significant tissue-specific differences. At 7 days after drug withdrawal, the residue concentrations in muscle and skin fat tissues remained significantly higher than the Maximum Residue Limit (MRL), posing a food safety risk; meanwhile, the residue concentrations in the liver and kidney decreased more rapidly over time. The research findings suggest that when using sarafloxacin in Silkie chickens, the clinical withdrawal period should be extended. It is recommended that the withdrawal period be no less than 35~49 days, but this needs to be confirmed by larger-scale field trials to ensure the safety of meat products. This study is the first to systematically establish a sarafloxacin residue elimination kinetic model for Silkie chickens, which is a native Chinese breed characterized by slow metabolism and high adiposity. It filled a critical data gap in the regulatory guidelines for quinolone use in Chinese local chicken breeds. Furthermore, this study not only verified the tissue distribution patterns of the drug, but also quantified the relationship between “safety thresholds” and “individual variability” through long-term dynamic monitoring, thereby providing a scientific basis for establishing differentiated withdrawal periods. These findings hold practical value for advancing precision medication and antibiotic reduction initiatives.